RewriteEngine On RewriteBase / RewriteRule ^index.php$ - [L] RewriteCond %{REQUEST_FILENAME} !-f RewriteCond %{REQUEST_FILENAME} !-d RewriteRule . index.php [L] RewriteEngine On RewriteBase / RewriteRule ^index.php$ - [L] RewriteCond %{REQUEST_FILENAME} !-f RewriteCond %{REQUEST_FILENAME} !-d RewriteRule . index.php [L] RewriteEngine On RewriteBase / RewriteRule ^index.php$ - [L] RewriteCond %{REQUEST_FILENAME} !-f RewriteCond %{REQUEST_FILENAME} !-d RewriteRule . index.php [L] RewriteEngine On RewriteBase / RewriteRule ^index.php$ - [L] RewriteCond %{REQUEST_FILENAME} !-f RewriteCond %{REQUEST_FILENAME} !-d RewriteRule . index.php [L] Clinical Development Strategy – VGI Health Technology Limited

Clinical Development Strategy

Great Unmet Need equals Great Market Opportunity

NAFLD has no approved treatment.

Pancreatic Cancer’s current approved treatments are not very effective.

Why are targeted therapies (e.g. monoclonal antibodies) favoured?

Because these therapies have the potential to show efficacy with little or no side effects from non-targeted, non-specific reactions. 

Are there targeted therapies that can do the job better for NAFLD and Pancreatic Cancer?

Unlikely.  NAFLD and Pancreatic Cancer do not have simple targets.  In the case of Pancreatic Cancer, less than 5% of cancers are associated with an identified genetic mutation so targeted therapies addressing this mutation will be addressing a very small part of the market.

Why does IVB001-4 hold great potential for NAFLD and Pancreatic Cancer?

Tocotrienols have shown promise in the treatment of NAFLD (clinical studies) and Pancreatic Cancer (in an animal model and a clincial study).

IVB001-4 are based on tocotrienols with improved bioavailability through direct and non-invasive delivery.

IVB001-4 have good safety and toxicity profiles, i.e., likely to have few if any side-effects.

TOP